Traditional cures-maker Bohai ready for liftoff as China expands healthcare

Traditional Chinese medicine maker Bohai Pharmaceuticals has been grabbing headlines lately as well as the interest of investors. The company added five products to its offerings this month: three prescription drugs and two OTC medicines. Investor interest is piqued by ambitious Chinese government healthcare reforms that aim to make such drugs affordable to the rural poor--the majority of China's population. Article

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.